Search results for " reflux"

showing 6 items of 126 documents

Delayed-Onset Superior Mesenteric Artery Syndrome Presenting as Oesophageal Peptic Stricture

2012

Superior mesenteric artery (SMA) syndrome is an infrequent cause of vomiting and weight loss due to compression of the third part of the duodenum by the SMA. We describe the case of a 17-year-old woman, admitted to our department for progressive dysphagia and severe weight loss due to an oesophageal peptic stricture, caused by chronic acid reflux secondary to duodenal compression by the SMA. Symptoms improved after (par)enteral nutrition and repeated oesophageal dilatation, thus supporting the role of intensive medical and endoscopic intervention as an alternative to surgery, at least in some cases.

medicine.medical_specialtySettore MED/09 - Medicina InternaPepticGastroenterologymedicine.arteryInternal medicinemedicineOesophageal dilatationSuperior mesenteric arterySuperior mesenteric artery syndromelcsh:RC799-869Settore MED/12 - Gastroenterologiabusiness.industryGastroenterologymedicine.diseaseSMA*DysphagiaParenteral nutritionmedicine.anatomical_structureVomitingDuodenumlcsh:Diseases of the digestive system. Gastroenterologymedicine.symptomPublished online: March 2012businessSuperior mesenteric artery syndromeChronic acid refluxCase Reports in Gastroenterology
researchProduct

Do we understand the pathophysiology of GERD after sleeve gastrectomy?

2020

Gastroesophageal reflux disease (GERD), a prevalent problem among obese individuals, is strongly associated with obesity and weight loss. Hence, bariatric surgery effectively improves GERD for many patients. Depending on the type of bariatric procedure, however, surgery can also worsen or even cause a new onset of GERD. As a consequence, GERD remains a relevant problem for many bariatric patients, and especially those who have undergone sleeve gastrectomy (SG). Affected patients report not only a decrease in physical functioning but also suffer from mental and emotional problems, resulting in poorer social functioning. The pathomechanism of GERD after SG is most likely multifactorial and tr…

medicine.medical_specialtySleeve gastrectomymedicine.medical_treatmentBariatric Surgery030209 endocrinology & metabolismDiseaseGeneral Biochemistry Genetics and Molecular BiologyEsophageal Sphincter LowerHiatal hernia03 medical and health sciences0302 clinical medicinePostoperative ComplicationsHistory and Philosophy of ScienceWeight lossGastrectomyWeight LossMedicineHumansObesityIntensive care medicinebusiness.industryGeneral Neurosciencemedicine.diseaseObesityhumanitiesdigestive system diseasesPathophysiologyHernia HiatalTreatment OutcomeGERDGastroesophageal Reflux030211 gastroenterology & hepatologyGastrectomymedicine.symptombusinessAnnals of the New York Academy of SciencesReferences
researchProduct

The fate of implant after endoscopic injection of dextranomer/hyaluronic acid in vesicoureteral reflux: time to partial reabsorption and stabilization

2020

Summary Background/introduction Vesicoureteral reflux (VUR) potentially leads to renal damage, scarring, and eventually end-stage renal disease. Endoscopic treatment is well tolerated in children, it has reduced costs, and it effectively prevents urinary tract infections (UTIs), while avoiding long term antibiotics use. Objective With the aim to investigate the time needed to reach the stabilization of the dextranomer/hyaluronic acid (Dx/HA) implants and to identify cut-off heights to ensure the success of the procedure, the authors analyzed ultrasonographic (US) intra-operative appearance of the mounds following endoscopic treatment for VUR and repeated the measurements during serial posto…

medicine.medical_specialtyVoiding cystourethrogramUrologyUrinary system030232 urology & nephrologyVesicoureteral reflux03 medical and health sciences0302 clinical medicine030225 pediatricsmedicineHumansHyaluronic AcidAntibiotic prophylaxisChildMound heightRetrospective StudiesVesico-Ureteral Refluxmedicine.diagnostic_testReabsorptionbusiness.industryVesicoureteral refluxRefluxInfantDextransmedicine.diseaseSurgeryTreatment OutcomeReabsorptionSub-ureteral injectionPediatrics Perinatology and Child HealthDextranomerImplantbusinessmedicine.drugJournal of Pediatric Urology
researchProduct

Main Topics

2012

medicine.medical_specialtybusiness.industryGastro-esophageal reflux diseasemedicine.diseaseGastroenterologyNeurologyInternal medicineGERDmedicinePhysical therapyNeurology (clinical)businessEsophageal motilityDirect stimulationEuropean Journal of Neurology
researchProduct

Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.

2007

Proton pump inhibitors (PPIs) are antisecretory agents that are widely used in the short- and long-term management of gastroesophageal reflux disease (GERD) to relieve symptoms, heal esophagitis, and prevent complications, such as strictures and Barrett’s esophagus. The total healthcare costs of GERD are high, especially for maintenance treatment. Therefore, the choice of cost-effective therapeutic options is an ineluctable challenge for public health authorities, third-party payers, and patients. In some European Union countries, a recent trend of public health authorities is to promote the choice of less expensive PPIs, regardless of their antisecretory potency – this in spite of the evid…

medicine.medical_specialtybusiness.industryGastroenterologyRefluxAntisecretory agentsEsomeprazoleProton Pump InhibitorsDiseaseProton pump inhibitorGastroesophageal reflux diseasemedicine.diseaseGastroenterologydigestive system diseasesInternal medicineGERDmedicineGastroesophageal RefluxHumansbusinessEsophagitisTherapy optimizationRandomized Controlled Trials as TopicDigestion
researchProduct

Maintenance therapy in gastro-oesophageal reflux disease.

2005

Gastro-oesophageal reflux disease (GORD) is a chronic condition. Symptom control and the maintenance of healing of erosive oesophagitis, if present, are important topics. In patients responding to a proton pump inhibitor (PPI) and showing no treatment symptoms it is appropriate to consider long-term treatment strategies, whether continuous, intermittent or on demand. Maintenance PPI therapy is well tolerated for up to 10 years of continuous use. Furthermore, tachyphylaxis does not occur during long-term maintenance PPI therapy. Previous concerns about risks of long-term PPI therapy in Heliobacter pylori-negative or H. pylori-positive patients have not materialized, while no cases of intesti…

medicine.medical_specialtymedicine.drug_classProton-pump inhibitorGastroenterologyDrug Administration ScheduleEsomeprazoleHiatal herniaPharmacotherapyMaintenance therapyInternal medicinemedicineHumansPharmacology (medical)SurvivorsSurgical teambusiness.industryEsophageal diseaseDecision TreesHeartburnEndoscopyProton Pump Inhibitorsmedicine.diseaseAnti-Ulcer Agentsdigestive system diseasesGastroesophageal Refluxmedicine.symptombusinessmedicine.drugDrugs
researchProduct